Compare CHRD & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHRD | TGTX |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | 676 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.5B |
| IPO Year | N/A | 2008 |
| Metric | CHRD | TGTX |
|---|---|---|
| Price | $112.93 | $52.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $149.17 | $49.80 |
| AVG Volume (30 Days) | 804.9K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $12.56 | $49.08 |
| Revenue Next Year | N/A | $26.69 |
| P/E Ratio | ★ $34.53 | $446.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $84.25 | $25.37 |
| 52 Week High | $151.95 | $57.38 |
| Indicator | CHRD | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.91 | 64.31 |
| Support Level | $86.73 | $28.57 |
| Resistance Level | $150.29 | $57.38 |
| Average True Range (ATR) | 3.62 | 2.34 |
| MACD | -1.27 | -0.14 |
| Stochastic Oscillator | 10.52 | 48.00 |
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.